Al­lo­gene Ther­a­peu­tics plans re­struc­tur­ing as it swaps out PhII CAR-T tri­al plans to leapfrog ri­vals

Al­lo­gene Ther­a­peu­tics is switch­ing up clin­i­cal plans for its off-the-shelf CAR-T ther­a­pies. In a bid to leapfrog more es­tab­lished ri­vals, the South San Fran­cis­co biotech will de­pri­or­i­tize two cur­rent Phase II tri­als of its lead can­di­date — its most ad­vanced — and launch a new late-stage study with a much dif­fer­ent de­sign, it an­nounced late Thurs­day.

As a re­sult of the new ap­proach, Al­lo­gene will al­so im­ple­ment a “planned re­struc­tur­ing” this quar­ter to align with the small­er tri­al foot­print and pri­or­i­tized pipeline, the biotech said in a re­lease. While it didn’t spell out spe­cif­ic im­pli­ca­tions, the move is ex­pect­ed to ex­tend its run­way from 2025 in­to 2026.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER